Carcinoid tumor

Summary

Carcinoid tumor (MONDO:0005369) is a cancer (an umbrella term covering 7 Mondo subtypes) with 4 cohort genes (4 GWAS associations across 1 studies; 1 CIViC-evidence somatic driver) and 67 clinical trials. Top therapeutic interventions include edotreotide gallium ga-68, lanreotide, and pasireotide.

At a glance

• Classification: Cancer
• Umbrella term: 7 Mondo subtypes
• Cohort genes: 4
• GWAS associations: 4
• Clinical trials: 67

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	carcinoid tumor
Mondo ID	MONDO:0005369
EFO	EFO:0004243
MeSH	D002276
NCIT	C2915
SNOMED CT	443492008
UMLS	C0007095
MedGen	2838
GARD	0024176
Is cancer (heuristic)	yes

Also known as: carcinoid · carcinoid tumor · carcinoid tumor (disease) · carcinoid tumour (disease) · NET G1 · neuroendocrine neoplasm G1 · neuroendocrine tumor G1 · neuroendocrine tumour G1

Data availability: 4 GWAS associations (1 study) · 1 HPO phenotype.

Disease family

An umbrella term covering 7 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › endocrine gland neoplasm › neuroendocrine neoplasm › carcinoid tumor

Related subtypes (13): paraganglioma, neuroendocrine carcinoma, prostate neuroendocrine neoplasm, ovarian neuroendocrine neoplasm, breast neuroendocrine neoplasm, lung neuroendocrine neoplasm, laryngeal neuroendocrine neoplasm, middle ear neuroendocrine tumor, hereditary pheochromocytoma-paraganglioma, bronchial endocrine tumor, thymic neuroendocrine tumor, uterine corpus neuroendocrine neoplasm, digestive system neuroendocrine neoplasm

Subtypes (7): lung carcinoid tumor, atypical carcinoid tumor, gastric neuroendocrine tumor G1, somatostatinoma, intestinal neuroendocrine tumor G1, pancreatic neuroendocrine tumor G1, childhood carcinoid tumor

Genetics & variants

GWAS landscape

4 GWAS associations across 1 studies. Top hits map to 4 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs2208059	4e-07	KIF16B	?	2.42
rs10089	2e-06	SLC12A2	?	2.56
rs975121	7e-06	FGF12	?	2.17
rs2206734	8e-06	CDKAL1	?	3.45

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST000908	Walsh KM	2010	239	0	A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	1
Tier 3: regulatory	0
Tier 4: intronic/intergenic	3

MAF distribution

Bucket	Variants
common (>=0.05)	4
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	3
3_prime_UTR_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs2208059	20	16330665	T>C	0.05	intron_variant	KIF16B	4e-07	Tier 4: intronic/intergenic
rs10089	5	128186851	C>A,T	0.05	3_prime_UTR_variant	SLC12A2	2e-06	Tier 2: splice/UTR
rs975121	3	192179429	G>A,C	0.05	intron_variant	FGF12	7e-06	Tier 4: intronic/intergenic
rs2206734	6	20694653	C>A,G,T	0.05	intron_variant	CDKAL1	8e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
SLC12A2			CIViC #5323

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SLC12A2	Orphanet:633021	SLC12A2-related autosomal recessive neonatal-developmental delay-intellectual disability-feeding difficulty-sensorineural deafness syndrome
SLC12A2	Orphanet:633024	SLC12A2-related autosomal dominant infantile-developmental delay-intellectual disability-sensorineural deafness syndrome
FGF12	Orphanet:442835	Non-specific early-onset epileptic encephalopathy

Cohort genes → proteins

4 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	4

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SLC12A2	HGNC:10911	ENSG00000064651	P55011	Solute carrier family 12 member 2	gwas
KIF16B	HGNC:15869	ENSG00000089177	Q96L93	Kinesin-like protein KIF16B	gwas
CDKAL1	HGNC:21050	ENSG00000145996	Q5VV42	Threonylcarbamoyladenosine tRNA methylthiotransferase	gwas
FGF12	HGNC:3668	ENSG00000114279	P61328	Fibroblast growth factor 12	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SLC12A2	Solute carrier family 12 member 2	Cation-chloride cotransporter which mediates the electroneutral transport of chloride, potassium and/or sodium ions across the membrane.
KIF16B	Kinesin-like protein KIF16B	Plus end-directed microtubule-dependent motor protein involved in endosome transport and receptor recycling and degradation.
CDKAL1	Threonylcarbamoyladenosine tRNA methylthiotransferase	Catalyzes the methylthiolation of N6-threonylcarbamoyladenosine (t(6)A), leading to the formation of 2-methylthio-N6-threonylcarbamoyladenosine (ms(2)t(6)A) at position 37 in tRNAs that read codons beginning with adenine.
FGF12	Fibroblast growth factor 12	Involved in nervous system development and function.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.25

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Enzyme (other)	1	3.0×	0.404
Other/Unknown	3	1.3×	0.404

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SLC12A2	Other/Unknown	no		SLC12A1/SLC12A2, NKCC1, AA-permease/SLC12A_dom
KIF16B	Enzyme (other)	yes	5.6.1.3	FHA_dom, PX_dom, Kinesin_motor_dom
CDKAL1	Other/Unknown	no		TRAM_dom, Methylthiotransferase, MiaB-like_arc_euk
FGF12	Other/Unknown	no		Fibroblast_GF_fam, IL1/FGF

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	4
unknown	0

Top tissues across cohort

Tissue	Cohort genes
inferior vagus X ganglion	1
palpebral conjunctiva	1
parotid gland	1
colonic mucosa	1
jejunal mucosa	1
sural nerve	1
buccal mucosa cell	1
calcaneal tendon	1
ganglionic eminence	1
cardiac atrium	1
cardiac muscle of right atrium	1
right atrium auricular region	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SLC12A2	277	ubiquitous	marker	palpebral conjunctiva, parotid gland, inferior vagus X ganglion
KIF16B	261	ubiquitous	marker	sural nerve, jejunal mucosa, colonic mucosa
CDKAL1	201	ubiquitous	marker	buccal mucosa cell, calcaneal tendon, ganglionic eminence
FGF12	204	broad	marker	right atrium auricular region, cardiac atrium, cardiac muscle of right atrium

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CDKAL1	2,724
SLC12A2	2,461
FGF12	1,639
KIF16B	995

Structural data

PDB: 3 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
SLC12A2	P55011	14
KIF16B	Q96L93	2
FGF12	P61328	2

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
CDKAL1	Q5VV42	82.72

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 16. Enrichment computed across 4 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Cation-coupled Chloride cotransporters	1	407.9×	0.039	SLC12A2
tRNA processing	1	89.2×	0.054	CDKAL1
Phase 0 - rapid depolarisation	1	86.5×	0.054	FGF12
tRNA modification in the nucleus and cytosol	1	73.2×	0.054	CDKAL1
Kinesins	1	44.6×	0.067	KIF16B
Golgi-to-ER retrograde transport	1	33.2×	0.067	KIF16B
R-HSA-425393	1	32.4×	0.067	SLC12A2
COPI-dependent Golgi-to-ER retrograde traffic	1	27.7×	0.067	KIF16B
Intra-Golgi and retrograde Golgi-to-ER traffic	1	26.2×	0.067	KIF16B
Factors involved in megakaryocyte development and platelet production	1	16.6×	0.094	KIF16B
SLC-mediated transmembrane transport	1	14.8×	0.096	SLC12A2
Metabolism of RNA	1	10.4×	0.117	CDKAL1
Membrane Trafficking	1	9.3×	0.117	KIF16B
Hemostasis	1	9.0×	0.117	KIF16B
Vesicle-mediated transport	1	8.7×	0.117	KIF16B
Transport of small molecules	1	6.3×	0.150	SLC12A2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
tRNA methylthiolation	1	4213.0×	0.003	CDKAL1
positive regulation of cell volume	1	4213.0×	0.003	SLC12A2
regulation of voltage-gated sodium channel activity	1	4213.0×	0.003	FGF12
formation of primary germ layer	1	2106.5×	0.003	KIF16B
inorganic anion import across plasma membrane	1	2106.5×	0.003	SLC12A2
inorganic cation import across plasma membrane	1	2106.5×	0.003	SLC12A2
positive regulation of aspartate secretion	1	2106.5×	0.003	SLC12A2
regulation of matrix metallopeptidase secretion	1	2106.5×	0.003	SLC12A2
maintenance of translational fidelity	1	1404.3×	0.004	CDKAL1
regulation of neuronal action potential	1	1053.2×	0.005	FGF12
regulation of spontaneous synaptic transmission	1	1053.2×	0.005	SLC12A2
negative regulation of vascular wound healing	1	842.6×	0.005	SLC12A2
transepithelial ammonium transport	1	842.6×	0.005	SLC12A2
regulation of receptor recycling	1	702.2×	0.005	KIF16B
transepithelial chloride transport	1	468.1×	0.007	SLC12A2
ammonium transmembrane transport	1	468.1×	0.007	SLC12A2
hyperosmotic response	1	421.3×	0.007	SLC12A2
intracellular chloride ion homeostasis	1	421.3×	0.007	SLC12A2
chloride ion homeostasis	1	383.0×	0.007	SLC12A2
T cell chemotaxis	1	280.9×	0.008	SLC12A2
receptor catabolic process	1	280.9×	0.008	KIF16B
Golgi to endosome transport	1	263.3×	0.008	KIF16B
cellular response to potassium ion	1	263.3×	0.008	SLC12A2
regulation of sodium ion transmembrane transport	1	263.3×	0.008	FGF12
intracellular potassium ion homeostasis	1	247.8×	0.008	SLC12A2
cellular response to chemokine	1	247.8×	0.008	SLC12A2
sodium ion homeostasis	1	234.1×	0.009	SLC12A2
vesicle transport along microtubule	1	221.7×	0.009	KIF16B
positive regulation of sodium ion transport	1	210.7×	0.009	FGF12
intracellular sodium ion homeostasis	1	191.5×	0.009	SLC12A2

Therapeutics

Drugs indicated for this disease

1 approved, 5 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
INTERFERON ALFA-2B	Approved (phase 4)
Edotreotide	Phase 3 (in late-stage trials)
Everolimus	Phase 3 (in late-stage trials)
Lanreotide	Phase 3 (in late-stage trials)
Octreotide	Phase 3 (in late-stage trials)
Pasireotide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Aflibercept, Axitinib, Bevacizumab, Cabozantinib, Carboplatin, Catequentinib, Cisplatin, Estradiol, Etoposide, Famitinib, Filgrastim, Floxuridine, Fluorouracil, Ibrutinib, Ipilimumab, Nintedanib, Nivolumab, Oxaliplatin, PEGINTERFERON ALFA-2B, Patupilone, Pegfilgrastim, Pembrolizumab, Ramucirumab, Somatostatin, Sunitinib, Temozolomide, Temsirolimus.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 3

Druggability breadth: 2 of 4 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
SLC12A2	BUMETANIDE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SLC12A2	1	4
KIF16B	0	0
CDKAL1	0	0
FGF12	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
BUMETANIDE	4	SLC12A2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
SLC12A2	13	Binding:9, Functional:4
CDKAL1	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
KIF16B	5.6.1.3	plus-end-directed kinesin ATPase

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

1 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
BUMETANIDE	4	SLC12A2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	SLC12A2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	KIF16B
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	CDKAL1, FGF12

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
KIF16B	0	—
CDKAL1	1	—
FGF12	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 67.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	30
Not specified	16
PHASE1	10
PHASE3	5
PHASE1/PHASE2	4
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05477576	PHASE3	RECRUITING	Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
NCT07087054	PHASE3	RECRUITING	Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT00227136	PHASE3	TERMINATED	Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
NCT00412061	PHASE3	COMPLETED	Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
NCT01373736	PHASE3	UNKNOWN	123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
NCT02628067	PHASE2	ACTIVE_NOT_RECRUITING	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT02754297	PHASE2	ACTIVE_NOT_RECRUITING	Personalized PRRT of Neuroendocrine Tumors
NCT03950609	PHASE2	ACTIVE_NOT_RECRUITING	Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
NCT05263050	PHASE2	RECRUITING	Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
NCT05969860	PHASE2	RECRUITING	At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT06790706	PHASE2	RECRUITING	IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
NCT00050349	PHASE2	COMPLETED	EPO906 in Carcinoid and Other Neuroendocrine Tumors
NCT00088595	PHASE2	COMPLETED	Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
NCT00328497	PHASE2	COMPLETED	A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
NCT00688623	PHASE2	COMPLETED	RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
NCT00780663	PHASE2	COMPLETED	Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
NCT00947167	PHASE2	TERMINATED	A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
NCT01024387	PHASE2	COMPLETED	AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
NCT01175096	PHASE1/PHASE2	UNKNOWN	Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
NCT01253161	PHASE2	COMPLETED	Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
NCT01327612	PHASE2	COMPLETED	Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
NCT01435122	PHASE2	COMPLETED	A Study of Axitinib in Advanced Carcinoid Tumors
NCT01466036	PHASE2	COMPLETED	Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT01619865	PHASE1/PHASE2	COMPLETED	Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
NCT01731925	PHASE2	UNKNOWN	A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
NCT01782443	PHASE2	COMPLETED	Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
NCT02038738	PHASE1/PHASE2	UNKNOWN	68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
NCT02177773	PHASE1/PHASE2	TERMINATED	GA-68 DOTA-TOC of Somatostatin Positive Malignancies
NCT02399215	PHASE2	COMPLETED	Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT02441062	PHASE2	COMPLETED	Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
NCT02575300	PHASE2	COMPLETED	Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
NCT02795858	PHASE2	COMPLETED	A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
NCT02859064	PHASE2	TERMINATED	Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
NCT03420521	PHASE2	TERMINATED	Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
NCT04039516	PHASE2	UNKNOWN	Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
NCT04197310	PHASE2	COMPLETED	Cabozantinib and Nivolumab for Carcinoid Tumors
NCT04915144	PHASE2	WITHDRAWN	177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
NCT05361668	PHASE2	COMPLETED	Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
NCT05987176	PHASE2	TERMINATED	Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
NCT07165132	PHASE1	RECRUITING	Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EDOTREOTIDE GALLIUM GA-68	4	5
LANREOTIDE	4	3
PASIREOTIDE	4	3
LUTETIUM OXODOTREOTIDE LU-177	4	2
OCTREOTIDE	4	2
AXITINIB	4	1
CABOZANTINIB	4	1
EVEROLIMUS	4	1
NINTEDANIB	4	1
PERTUZUMAB	4	1
PIFLUFOLASTAT F18	4	1
RAMUCIRUMAB	4	1
SUNITINIB	4	1
PALTUSOTINE	3	2
VELIPARIB	3	2
ACTINIUM AC 225 DOTATATE	3	1
DOMVANALIMAB	3	1
GANITUMAB	3	1
SOMATOSTATIN	3	1
ZIMBERELIMAB	3	1
CONATUMUMAB	2	1
GALLIUM	2	1
LUTETIUM LU177 EDOTREOTIDE	2	1
QUARFLOXIN	2	1
ZENIDOLOL	2	1
CHEMBL3350037	0	2
CHEMBL4215501	0	2
CHEMBL4849721	0	2
EXELIXIS	0	2
CHEMBL4079877	0	1